CD8A and neoplasm: The prerequisite to evaluate the therapeutic effect of α -RIT and ACT combination was to develop a suitable tumor model expressing two antigens, the first one allowing targeting with a radiolabeled antibody (CD138) and the second one for specific OT-I CD8+ T cell recognition (H2Kb/OVA257–264 complexes).